Nebenwirkungen · Kesimpta
Kesimpta 20 mg solution for injection in pre-filled syringe Kesimpta 20 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 8
HOS-147277 · Präparat HOS-099626
The incidence of SIRRs was highest with the first injection (14.4%), decreasing significantly with subsequent injections (4.4% with second, <3% from third injection). SIRRs were mostly (99.8%) mild to moderate in severity. Two (0.2%) ofatumumab-treated MS patients reported serious injection-related reactions but not life-threatening. The most frequently reported symptoms (≥2%) included fever, headache, myalgia, chills and fatigue. Additional reported symptoms included nausea (1.7%) and vomiting (0.6%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T09:12:00Z · SHA-256 ed664d69f2ab08357f5c6bef67c5703b48d58168dfbd3efdb846833c378f7fb1 · Passage dce2874841f0701e0e222ce8534ff20293ef3520621f7d7d35208fed3a53781d · Zeichen 4101–4608 im Abschnitt